Background and aims Inflammation, oxidative stress, matrix degradation, medial calcification
and vascular smooth muscle cell (VSMC) loss are prominent features in abdominal aortic …

Background and aims Abdominal aortic aneurysms (AAA) is a chronic inflammatory disease
in which signal transducer and activator of transcription 3 (STAT3), and disintegrin and …

Abdominal aortic aneurysm (AAA) is a chronic inflammatory disease characterized by aortic
dilatation and predominantly affects an elderly population. Accumulating evidence suggests …

Abdominal aortic aneurysm (AAA) is a degenerative disease characterized by local
abnormal dilation of the aorta accompanied by vascular smooth muscle cell (VSMC) …

The rupture of an abdominal aortic aneurysm (AAA) causes about 200,000 deaths
worldwide each year. However, there are currently no effective drug therapies to prevent …

Background Abdominal aortic aneurysm (AAA) is a chronic vascular disease wherein the
inflammation of vascular smooth muscle cells (VSMCs) plays a pivotal role in its …

We have previously reported that activation of AMP-activated kinase alpha 2 (AMPKa2) by
nicotine or angiotensin II (AngII) instigates formation of abdominal aortic aneurysms (AAA) in …

An abdominal aortic aneurysm (AAA) is a permanent, localized dilatation of the abdominal
aorta. In western countries, the morbidity of AAA is approximately 8%. Currently …

Background Identifying effective drugs to suppress vascular inflammation is a promising
strategy to delay the progression of abdominal aortic aneurysm (AAA). Itaconate has a vital …

Methods AAA was induced in ApoE−/− mice by Ang II (Angiotensin II)-infusion. AICAR (5-
aminoimidazole-4-carboxamide-1-β-d-ribofuranoside) was used as AMPK activator and …